Literature DB >> 15240620

Effect of multiple endocrine neoplasia type 1 (MEN1) gene mutations on premature mortality in familial MEN1 syndrome with founder mutations.

T Ebeling1, O Vierimaa, S Kytölä, J Leisti, P I Salmela.   

Abstract

Estimation of mortality and the natural course of a disease is usually based on information of carefully studied individuals with or at risk for a specific disease. Genealogical information has rarely been accurate enough for such studies. With the help of church records and multiple endocrine neoplasia type 1 (MEN1) family information of the two founder MEN1 mutations in Northern Finland (1466del12 and 1657insC), we could trace back common ancestors born in the beginning of the 1700s (1466del12) and approximately 1850 (1657insC) and find 67 probable gene carriers born between 1728 and 1929, which were identified among their offspring. Information was gathered from 34 obligatory MEN1 gene carriers and 31 spouses. The mean age (+/- sd) of death of affected males (n = 16) was 61.1 +/- 12.0 yr vs. 65.8 +/- 15.3 yr for unaffected males (n = 16) and for affected females (n = 16) was 67.2 +/- 10.7 yr vs. 67.7 +/- 14.7 yr for unaffected females (n = 13). The ages of death of the obligatory heterozygotes did not differ from that of the spouses in sex groups or from the sex-matched life expectancy estimates derived from Finnish national statistics. Causes of death differed significantly between female probands and spouses. In conclusion, obligatory MEN1 gene carrier status did not show a harmful effect on survival in this retrospective analysis tracing back to almost 300 yr.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240620     DOI: 10.1210/jc.2003-031513

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition.

Authors:  O Vierimaa; A Villablanca; A Alimov; M Georgitsi; A Raitila; P Vahteristo; C Larsson; A Ruokonen; E Eloranta; T M L Ebeling; J Ignatius; L A Aaltonen; J Leisti; P I Salmela
Journal:  J Endocrinol Invest       Date:  2009-03-26       Impact factor: 4.256

2.  Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.

Authors:  Jonathan R Strosberg; Aejaz Nasir; Pamela Hodul; Larry Kvols
Journal:  Gastrointest Cancer Res       Date:  2008-05

3.  Thymic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1.

Authors:  Iina Yliaska; Heikki Tokola; Tapani Ebeling; Outi Kuismin; Olavi Ukkola; Minna L Koivikko; Timo Lesonen; Jussi Rimpiläinen; Tuuli Felin; Eeva Ryhänen; Saara Metso; Camilla Schalin-Jäntti; Pasi Salmela
Journal:  Endocrine       Date:  2022-06-13       Impact factor: 3.925

Review 4.  Multiple Endocrine Neoplasia Type 1: Latest Insights.

Authors:  Maria Luisa Brandi; Sunita K Agarwal; Nancy D Perrier; Kate E Lines; Gerlof D Valk; Rajesh V Thakker
Journal:  Endocr Rev       Date:  2021-03-15       Impact factor: 19.871

5.  Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.

Authors:  Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Marc J Berna; Robert T Jensen
Journal:  Medicine (Baltimore)       Date:  2013-05       Impact factor: 1.817

6.  Reduced life expectancy seen in hereditary diseases which predispose to early-onset tumors.

Authors:  D Gareth R Evans; Sarah Louise Ingham
Journal:  Appl Clin Genet       Date:  2013-07-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.